Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
English Funding Rejection For Lynparza Triggers Concern Over ‘Double Counting’ Costs
Sep 07 2022
•
By
Neena Brizmohun
NICE says Lynparza is too expensive for treating prostate cancer • Source: Alamy
More from Market Access
More from Pink Sheet